FDA keeps icosapent ethyl (Vascepa) approved for CV risk reduction based on REDUCE-IT
Shared summary that the FDA's approval of high-dose EPA stays in place despite debate over the mineral oil placebo in REDUCE-IT. It is indicated as add-on to statins for adults with triglycerides at least 150 mg/dL and established CVD, or diabetes plus two risk factors. Atrial fibrillation and bleeding were more common.